195 related articles for article (PubMed ID: 25938220)
1. The molecular medicine of acid ceramidase.
Frohbergh M; He X; Schuchman EH
Biol Chem; 2015 Jun; 396(6-7):759-65. PubMed ID: 25938220
[TBL] [Abstract][Full Text] [Related]
2. Acid ceramidase and human disease.
Park JH; Schuchman EH
Biochim Biophys Acta; 2006 Dec; 1758(12):2133-8. PubMed ID: 17064658
[TBL] [Abstract][Full Text] [Related]
3. Spinal muscular atrophy associated with progressive myoclonus epilepsy.
Topaloglu H; Melki J
Epileptic Disord; 2016 Sep; 18(S2):128-134. PubMed ID: 27647482
[TBL] [Abstract][Full Text] [Related]
4. Acid Ceramidase Depletion Impairs Neuronal Survival and Induces Morphological Defects in Neurites Associated with Altered Gene Transcription and Sphingolipid Content.
Kyriakou K; Lederer CW; Kleanthous M; Drousiotou A; Malekkou A
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111095
[TBL] [Abstract][Full Text] [Related]
5. Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy.
Schuchman EH
Biochim Biophys Acta; 2016 Sep; 1862(9):1459-71. PubMed ID: 27155573
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Novel Acid Sphingomyelinase Activity Associated with Recombinant Human Acid Ceramidase.
He X; Schuchman EH
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002305
[TBL] [Abstract][Full Text] [Related]
7. Zebrafish acid ceramidase: Expression in Pichia pastoris GS115and biochemical characterization.
Rajput VB; Karthikeyan M; Ramasamy S
Int J Biol Macromol; 2019 Feb; 122():587-593. PubMed ID: 30399382
[TBL] [Abstract][Full Text] [Related]
8. Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy.
Gan JJ; Garcia V; Tian J; Tagliati M; Parisi JE; Chung JM; Lewis R; Baloh R; Levade T; Pierson TM
Neuromuscul Disord; 2015 Dec; 25(12):959-63. PubMed ID: 26526000
[TBL] [Abstract][Full Text] [Related]
9. Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.
Morad SA; Levin JC; Tan SF; Fox TE; Feith DJ; Cabot MC
Biochim Biophys Acta; 2013 Dec; 1831(12):1657-64. PubMed ID: 23939396
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.
Alves MQ; Le Trionnaire E; Ribeiro I; Carpentier S; Harzer K; Levade T; Ribeiro MG
Mol Genet Metab; 2013 Jul; 109(3):276-81. PubMed ID: 23707712
[TBL] [Abstract][Full Text] [Related]
11. ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy.
Elsea SH; Solyom A; Martin K; Harmatz P; Mitchell J; Lampe C; Grant C; Selim L; Mungan NO; Guelbert N; Magnusson B; Sundberg E; Puri R; Kapoor S; Arslan N; DiRocco M; Zaki M; Ozen S; Mahmoud IG; Ehlert K; Hahn A; Gokcay G; Torcoletti M; Ferreira CR
Hum Mutat; 2020 Sep; 41(9):1469-1487. PubMed ID: 32449975
[TBL] [Abstract][Full Text] [Related]
12. ASAH1 variant causing a mild SMA phenotype with no myoclonic epilepsy: a clinical, biochemical and molecular study.
Filosto M; Aureli M; Castellotti B; Rinaldi F; Schiumarini D; Valsecchi M; Lualdi S; Mazzotti R; Pensato V; Rota S; Gellera C; Filocamo M; Padovani A
Eur J Hum Genet; 2016 Nov; 24(11):1578-1583. PubMed ID: 27026573
[TBL] [Abstract][Full Text] [Related]
13. Development of an acid ceramidase activity-based probe.
Ouairy CM; Ferraz MJ; Boot RG; Baggelaar MP; van der Stelt M; Appelman M; van der Marel GA; Florea BI; Aerts JM; Overkleeft HS
Chem Commun (Camb); 2015 Apr; 51(28):6161-3. PubMed ID: 25748248
[TBL] [Abstract][Full Text] [Related]
14. Evidence for clinical, genetic and biochemical variability in spinal muscular atrophy with progressive myoclonic epilepsy.
Dyment DA; Sell E; Vanstone MR; Smith AC; Garandeau D; Garcia V; Carpentier S; Le Trionnaire E; Sabourdy F; Beaulieu CL; Schwartzentruber JA; McMillan HJ; ; Majewski J; Bulman DE; Levade T; Boycott KM
Clin Genet; 2014 Dec; 86(6):558-63. PubMed ID: 24164096
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the activation of acid ceramidase.
Gebai A; Gorelik A; Li Z; Illes K; Nagar B
Nat Commun; 2018 Apr; 9(1):1621. PubMed ID: 29692406
[TBL] [Abstract][Full Text] [Related]
16. Acid ceramidase deficiency: Farber disease and SMA-PME.
Yu FPS; Amintas S; Levade T; Medin JA
Orphanet J Rare Dis; 2018 Jul; 13(1):121. PubMed ID: 30029679
[TBL] [Abstract][Full Text] [Related]
17. Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes.
Li CM; Park JH; Simonaro CM; He X; Gordon RE; Friedman AH; Ehleiter D; Paris F; Manova K; Hepbildikler S; Fuks Z; Sandhoff K; Kolesnick R; Schuchman EH
Genomics; 2002 Feb; 79(2):218-24. PubMed ID: 11829492
[TBL] [Abstract][Full Text] [Related]
18. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.
Ramsubir S; Nonaka T; Girbés CB; Carpentier S; Levade T; Medin JA
Mol Genet Metab; 2008 Nov; 95(3):133-41. PubMed ID: 18805722
[TBL] [Abstract][Full Text] [Related]
19. Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
Beckmann N; Becker KA; Kadow S; Schumacher F; Kramer M; Kühn C; Schulz-Schaeffer WJ; Edwards MJ; Kleuser B; Gulbins E; Carpinteiro A
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835809
[TBL] [Abstract][Full Text] [Related]
20. Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls.
Momoi T; Ben-Yoseph Y; Nadler HL
Biochem J; 1982 Aug; 205(2):419-25. PubMed ID: 6814427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]